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ABSTRACT 
The present manuscript describe simple, sensitive, rapid, accurate, precise and economical Q-absorbance ratio method for the simultaneous 
determination of cefixime trihydrate and ofloxacin in combined tablet dosage form. Absorbance ratio method uses the ratio of absorbances at 
two selected wavelengths, one which is an isoabsorptive point and other being the λ-max of one of the two components. Cefixime trihydrate 
and ofloxacin show an isoabsorptive point at 280.2 nm in methanol. The second wavelength used is 291.4 nm, which is the λ-max of 
cefixime trihydrate in methanol. The linearity  was  obtained in the concentration range of 2-14 μg/ml for both cefixime trihydrate and 
ofloxacin. The concentrations of the drugs were determined by using ratio of absorbances at isoabsorptive point and at the λ-max of cefixime 
trihydrate. The method was successfully applied to pharmaceutical dosage form because no interference from the tablet excipients was 
found. The results of analysis have been validated statistically and by recovery studies.   
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INTRODUCTION
    
Cefixime trihydrate (CEFI), [6R, 7R] – 7- [[(2Z)- 2- (2-
amino thiazole- 4-yl)- [(carboxy methoxy ) imino] aetyl] 
amino]-3-ethenyl -8-oxo 5-thia 1-aza bicyclo [4.2.0] oct-
2-  ene-2  carboxylic  trihydrate  (Figure  1),  is  a  third 
generation  orally  acting  cephalosporin  antibiotic
1. 
Ofloxacin  (OFLO),  9-Fluro-2-3  dihydro-3-methyl-10- 
(4-methyl 1-piperazinyl) - 7-oxo-7H- pyrido [1, 2, 3-de] 
1,  4  benzoxazine-6-carboxylic  acid  (Figure  2),  is  a 
floroquinolone  antibiotic
2. This combination  is used  in 
the  treatment  of  typhoid  fever,  urinary  tract  infection, 
respiratory  tract  infection,  nosocomial  infections,  soft 
tissue  infections,  surgical  prophylaxis  and  intra-
abdominal  infections
3.  Literature  survey  reveals 
spectrophotometric
4,  HPLC
5  and  HPTLC
6  methods  for 
determination of CEFI in pharmaceutical dosage forms 
as well as in biological fluids. Literature survey reveals 
spectofluorimetric
7-8  and  HPLC
9-10  methods  for 
determination of OFLO in pharmaceutical dosage forms 
as well as in biological fluids. The combination of these 
two drugs is not official in any pharmacopoeia; hence no 
official  method  is  available  for  the  simultaneous 
estimation of CEFI and OFLO in their combined dosage 
forms.  Literature  survey  does  not  reveal  any  simple 
spectrophotometric  or  other  method  for  simultaneous 
estimation  of  CEFI  and  OFLO  in  combined  dosage 
forms.  The  present  communication  describes  simple, 
sensitive,  rapid,  accurate  and  economical 
spectrophotometric method for simultaneous estimation 
of both drugs in their combined tablet dosage forms. 
MATERIALS & METHODS 
Apparatus 
A  shimadzu  model  1700  (Japan)  double  beam 
UV/Visible spectrophotometer with spectral width of 2 
nm, wavelength accuracy of 0.5 nm and a pair of 10 mm 
matched quartz cell was used to measure absorbance of 
all the solutions. Spectra were automatically obtained by 
UV-Probe  system  software.  A  Sartorius  CP224S 
analytical  balance  (Gottingen,  Germany),  an  ultrasonic 
bath (Frontline  FS 4, Mumbai, India) was used  in the 
study.  
Reagents and Materials 
CEFI  and  OFLO  bulk  powder  was  kindly  gifted  by 
Acme  Pharmaceuticals  Ltd.  Ahmedabad,  India.  The 
commercial  fixed  dose  combination  product  was 
procured from the local market. Methanol AR Grade was 
procured  from  S.  D.  Fine  Chemicals  Ltd.,  Mumbai, 
India.  
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Preparation of standard stock solutions 
An  accurately  weighed  quantity  of  CEFI  (10  mg)  and 
OFLO  (10  mg)  were  transferred  to  a  separate 100  ml 
volumetric flask and dissolved and diluted to the mark 
with  methanol  to  obtain  standard  solution  having 
concentration  of  CEFI  (100  μg/ml)  and  OGLO  (100 
μg/ml).  
Methodology 
Absorbance ratio method uses the ratio of absorbances at 
two selected wavelengths, one which is an isoabsorptive 
point  and  other  being  the  λ-max  of  one  of  the  two 
components. From the overlay spectra of two drugs, it is 
evident  that  CEFI  and  OFLO  show  an  isoabsorptive 
point at 280.2 nm. The second wavelength used is 291.4 
nm,  which  is  the  λ-max  of  CEFI.  Seven  working 
standard solutions having concentration 2, 4, 6, 8, 10, 12 
and 14  μg/ml  for CEFI and 2, 4, 6, 8, 10, 12 and 14 
μg/ml  for  OFLO  were  prepared  in  methanol,  and  the 
absorbances at 280.2 nm (isoabsorptive point) and 291.4 
nm  (λ-max  of  CEFI)  were  measured  and  absorptivity 
coefficients were calculated using calibration curve. 
The concentration of two drugs in the  mixture  can  be 
calculated using following equations 
CX = [(QM – QY) / (QX -QY)] × A1/aX1          ...............(3)     
CY = (A1/aX1) – CX                                                 ………………(4)   
Where, A1 and A2 are absorbances of mixture at 280.2 
nm and 291.4 nm; and aX1 and aY1 are absorptivities of 
CEFI  and  OFLO  at  280.2  nm;  aX2  and  aY2  are 
absorptivities of CEFI and OFLO respectively at 291.4 
nm; and QM = A2 / A1, QX = aX2 / aX1 and QY = aY2 / 
aY1. 
Validation of the proposed method  
Linearity (Calibration curve) 
The calibration curves were plotted over a concentration 
range  of  2-14  μg/ml  for  each  CEFI  and  OFLO. 
Accurately  measured  standard  stock  solutions  of  each 
CEFI and OFLO (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4 ml) 
were  transferred  to  a  series  of  10  ml  volumetric  flask 
separately and diluted up to the mark with methanol. The 
absorbances of solution were then measured at 280.2 nm 
and 291.4 nm. The calibration curves were constructed 
by  plotting  absorbances  versus  concentration  and  the 
regression equations were calculated.        
Method precision (repeatability) 
The precision of the instrument was checked by repeated 
scanning  and  measurement  of  the  absorbances  of 
solutions (n = 6) of CEFI and OFLO (10 μg/ml for both 
drugs) without changing the parameters of the proposed 
method. 
 
 
Intermediate precision (reproducibility) 
The  intraday  and  interday  precisions  of  the  proposed 
method was determined by estimating the corresponding 
responses 3 times on the same day and on 3 different 
days  over  a  period  of  one  week  for  3  different 
concentrations of standard solutions of CEFI and OFLO 
(4, 8 and 12 μg/ml). The results were reported in terms of 
relative standard deviation (% RSD). 
Accuracy (recovery study) 
The  accuracy  of  the  method  was  determined  by 
calculating  the  recoveries  of  CEFI  and  OFLO  by  the 
standard addition method. Known amounts of standard 
solutions of CEFI and OFLO were at added at 50, 100 
and  150  %  level  to  prequantified  sample  solutions  of 
CEFI and OFLO (5 μg/ml for both drug). The amounts 
of CEFI and OFLO were estimated by applying obtained 
values to the respective regression line equations. 
Limit of detection and Limit of quantification  
The  limit  of  detection  (LOD)  and  the  limit  of 
quantification  (LOQ)  of  the  drug  were  derived  by 
calculating  the  signal-to-noise  ratio  (S/N,  i.e.,  3.3  for 
LOD  and  10  for  LOQ)  using  the  following  equations 
designated  by  International  Conference  on 
Harmonization (ICH) guidelines
11 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where, σ = the standard deviation of the response and S 
= slope of the calibration curve. 
Analysis  of  CEFI  and  OFLO  in  combined  tablet 
dosage form  
Twenty  tablets  were  weighed  and  the  average  weight 
was calculated. The tablet powder equivalent to 10 mg of 
CEFI and 10 mg of OFLO were weighed and transferred 
to 100 ml volumetric flask. Methanol (50 ml) was added 
and sonicated for 20 min. The volume is adjusted up to 
the mark with methanol. The solution was then filtered 
through Whatman filter paper no. 41. The solution was 
suitably  diluted  with  methanol  to  get  a  final 
concentration  of  10  μg/ml  of  CEFI  and  10  μg/ml  of 
OFLO. The absorbances of the sample solution i.e. A1 
and A2 were recorded at 280.2 nm (isoabsorptive point) 
and 291.4 nm (λ-max of CEFI) respectively, and ratios of 
absorbance  were  calculated,  i.e.  A2/A1.  Relative 
concentration of two drugs in the sample was calculated 
using above equation (3) and (4). The analysis procedure 
was repeated three times with tablet formulation.  
RESULTS & DISCUSSION 
In  absorbance  ratio  method  (Q-analysis),  the  primary 
requirement for developing a method for analysis is that 
the entire spectra should follow the Beer’s law at all the 
wavelength
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drugs. The two wavelengths were used for the analysis of 
the drugs were 280.2 nm (isoabsorptive point) and 291.4 
nm (λ-max of CEFI) at which the calibration curves were 
prepared for both the drugs. The overlain UV absorption 
spectra  of  CEFI  (291.4  nm)  and  OFLO  (298  nm) 
showing isoabsorptive point (280.2 nm) in methanol is 
shown in Figure 3. 
The  validation  parameters  were  studied  at  all  the 
wavelengths  for  the  proposed  method.  Accuracy  was 
determined  by  calculating  the  recovery,  and  the  mean 
was determined (Table 1). The method was successfully 
used  to  determine  the  amounts  of  CEFI  and  OFLO 
present in the tablet dosage forms. The results obtained 
were in good agreement with the corresponding labeled 
amount  (Table  2).  Precision  was  calculated  as 
repeatability and intra and inter day variations (% RSD) 
for both the drugs. Optical characteristics and summary 
of validation parameters for method is given in Table 3. 
By observing the validation parameters, the method was 
found  to  be  simple,  sensitive,  accurate  and  precise. 
Hence  the  method  can  be  employed  for  the  routine 
analysis of these two drugs in combined dosage form.    
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TABLE 1: RECOVERY DATA OF PROPOSED METHOD 
Drug  Level  Amount taken (µg/ml)  Amount added (µg/ml)  Amount found (µg/ml)  % Mean recovery ± S.D. (n = 3) 
 
 
OFLO 
I  5  2.5  7.59  101.2 ± 1.12 
II  5  5  9.97  99.70 ± 0.86 
III  5  7.5  12.43  99.44 ± 0.43 
 
CEFI 
I  5  2.5  7.54  100.5 ± 1.36 
II  5  5  9.96  99.60 ± 1.18 
III  5  7.5  12.57  100.6 ± 1.74 
 
 
TABLE 2: ANALYSIS OF OFLO AND CEFI BY PROPOSED METHOD 
Tablet 
 
Label claim (mg)  Amount found (mg)  % Label claim ± S. D. 
(n = 3) 
CEFI  OFLO  CEFI  OFLO)  CEFI  OFLO 
I 
200  200  199.4  197.9 
99.68 ± 0.84  98.95 ± 1.47 
II  200  200  202.4  198.6  101.2 ± 1.25  99.32 ± 0.97 
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TABLE 3: REGRESSION ANALYSIS DATA AND SUMMARY OF VALIDATION PARAMETERS FOR THE PROPOSED METHOD 
 
PARAMETERS  CEFI  OFLO  CEFI & OFLO 
Wavelength range (nm)  291.4  291.4  280.2 
Beer’s law limit (µg/ml)  2 - 14 l  2 - 14  2 - 14 
Regression equation  
(y = a + bc) 
Slope (b) 
Intercept (a) 
y = 0.043x-0.004 
0.043 
0.004 
y = 0.086x+0.019 
0.086 
0.019 
y = 0.037x+0.008 
0.037 
0.008 
Correlation Coefficient (r
2)  0.9982  0.9990  0.9980 
Sandell’s sensitivity (µg/cm
2/0.001 
A.U.) 
0.0240  0.0112  0.0255 
Molar extinction co-efficient 
(l mol
-1 cm
-1) 
21328.58  32537.30  19880.3 (CEFI) 
14155.9 (OFLO) 
Accuracy (Recovery) 
(n = 3) 
Level I  100.5 ± 1.36  101.2 ± 1.12  - 
Level II  99.60 ± 1.18  99.70 ± 0.86 
- 
Level III  100.6 ± 1.74  99.44 ± 0.43  - 
Method precision (Repeatability) 
(%RSD, n = 6), 
0.95  0.59  0.64 
Interday (n = 3) (%RSD
a)  0.32 - 1.37  0.27 - 1.09  0.48 - 1.84 
Intraday(n = 3) (%RSD)  0.30 – 1.25  0.24 – 0.99  0.55 - 1.88 
LOD
b (µg/ml)  0.42  0.46  0.36 
LOQ
c (µg/ml)  1.40  1.53  1.20 
Assay ± S.D. (n = 3)  100.44 ± 1.04  99.14 ± 1.22  - 
aRSD = Relative standard deviation. 
bLOD = Limit of detection. 
cLOQ = Limit of quantification 
 
 
Figure 1: Chemical structure of cefixime trihydrate (CEFI) 
 
Figure 2: Chemical structure of ofloxacin (OFLO) 
 
Figure 3: Overlain absorption spectra of CEFI (291.4 nm) and OFLO (298 nm) showing isoabsorptive point (280.2 nm) in methanol 
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